Data for Prothena’s NEOD001 to be Presented at the 58th

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Data for Prothena’s NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting

DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2 dose-escalation and expansion study will be highlighted in two oral presentations, and data highlighting quality of life measures in patients with AL amyloidosis will be featured in three posters at the 58 th Annual American Society of Hematology (ASH) Meeting to be held December 3-6, 2016, in San Diego, CA.

Clinical results of the Phase 1/2 dose-escalation and expansion study as of a May 9, 2016 data analysis were presented at the International Symposium on Amyloidosis (ISA) in Uppsala, Sweden on July 5, 2016. The two upcoming oral presentations at ASH will highlight additional aspects of the study results, as outlined below.

(Abstract #644) NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study

  • Presenter:  Morie A. Gertz, MD, Professor of Medicine, Mayo Clinic
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 7:15 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain updated patient case study data.

(Abstract #647) Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

  • Presenter:  Michaela Liedtke, MD, Stanford Comprehensive Cancer Center
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 8:00 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain data demonstrating that patients treated with monthly NEOD001 infusions had favorable organ response rates that were independent of time since prior plasma cell dyscrasia (PCD) treatment, depth of hematologic response, or predominant type of PCD treatment.

In addition, three posters that highlight quality of life measures in patients with AL amyloidosis will also be presented:

(Abstract #3596) Burden of AL Amyloidosis on Health-related Quality of Life in Clinic-based, Community-based, and Trial-based Studies

  • Presenter:  Spencer Guthrie, Head of Development Affairs, Prothena Biosciences Inc
  • Session:  904 – Outcomes Research – Malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location:  San Diego Convention Center, Hall GH

(Abstract #3586) Changes in Health-related Quality of Life Corresponding to Hematologic Response to Treatment in AL Amyloidosis

  • Presenter:  Vaishali Sanchorawala, M.D., Assoc. Director, Amyloidosis Center, Boston University Medical Center
  • Session:  903 – Outcomes Research – Non-malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location: San Diego Convention Center, Hall GH

(Abstract #4753) Treatment-related Symptoms and Impact on Health Related Quality of Life in AL Amyloidosis

  • Presenter:  Michelle K. White, PhD, Sr. Scientist and Sr. Director, Optum
  • Session:  903 – Outcomes Research – Non-malignant Conditions: Poster II
  • Date and Time:  Sunday, December 4, 6:00 – 8:00 PM, PT
  • Location:  San Diego Convention Center, Hall GH

About NEOD001

NEOD001 is a monoclonal antibody that specifically targets the circulating soluble amyloid and deposited insoluble amyloid that accumulates in both the AL and AA forms of amyloidosis. Patients with AL amyloidosis may be eligible to enroll in one of two clinical studies for NEOD001. The PRONTO study, a global, Phase 2b, double-blind, placebo-controlled, registration-directed study, will evaluate NEOD001 in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction, and will assess best response over 12 months of the cardiac functional biomarker NT-proBNP, defined by the consensus criteria of NT-proBNP change, in addition to other biomarker, quality of life and functional endpoints. The VITAL Amyloidosis Study, a global, Phase 3, double-blind, placebo-controlled, registrational study, is evaluating NEOD001 in newly-diagnosed, treatment-naïve patients with AL amyloidosis, and will assess a composite endpoint of all-cause mortality or cardiac hospitalizations in addition to biomarker, quality of life and functional endpoints. More information on the PRONTO study and The VITAL Amyloidosis Study is available at www.clinicaltrials.gov , by searching NCT #02632786 for PRONTO, and NCT #02312206 for VITAL or www.clinicaltrialsregister.eu , by searching EudraCT #2015-004318-14 for PRONTO, and EudraCT #2014-003865-11 for VITAL.

About AL Amyloidosis

Systemic amyloidoses are a complex group of progressive diseases caused by tissue deposition of misfolded proteins that result in progressive organ damage. The most common type, AL amyloidosis or primary amyloidosis, involves a hematological disorder caused by plasma cells that produce misfolded AL protein resulting in deposits of abnormal AL protein (amyloid) in the tissues and organs of individuals with this disease. There are no approved treatments for AL amyloidosis that directly target potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder and it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe suffer from this disease. Both the causes and origins of AL amyloidosis remain poorly understood. For more information on AL amyloidosis, please visit the websites of the Amyloidosis Support Group and the Amyloidosis Foundation .

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's website at www.prothena.com.

Contacts: Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Ellen Rose, Head of Communications 650-922-2405, ellen.rose@prothena.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 47

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 100

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 0

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 109

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 16

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 44

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 88

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading